Tag - NASH

Brookline starts CohBar at buy; PT $10

Brookline Capital Markets initiated coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and $10 price target. The stock closed at $2.63 on May 26. CohBar is developing CB4211, a novel and optimized analog of MOTS-c, a...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.